COMMUNIQUÉS West-GlobeNewswire

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK
02/09/2024
The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic and [...]
Myocene Helps the French Handball Team
02/09/2024
LIÈGE, Belgium, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Myocene, the Belgian sportstech company which is developing a device for the objective measurement of muscular fatigue for top-level sportsmen and women, today [...]
MYOCENE AU SERVICE DE L'ÉQUIPE DE FRANCE DE HANDBALL
02/09/2024
LIÈGE, Belgique, 02 sept. 2024 (GLOBE NEWSWIRE) -- Myocene, la sportstech liégeoise qui développe un dispositif de mesure objective de la fatigue musculaire à destination des sportifs de haut niveau, annonce aujourd’hui [...]
PCI Biotech: Employee share option scheme
02/09/2024
Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual General Meeting 24 May [...]
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
02/09/2024
Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, [...]
CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des personnes avec une sclérose en plaques...
02/09/2024
Le tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament ayant permis d’observer une réduction de l’accumulation du handicap chez des personnes présentant [...]
Claritas HealthTech Furthers its Capabilities in Urology with ReDisys™, a Computer Aided Detection Software for Kidney Cancer in CT Scans
02/09/2024
HONG KONG and LONDON, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Claritas HealthTech (“Claritas”) , a healthcare technology company specializing in medical image enhancement and Artificial Intelligence (AI) assisted diagnostic [...]
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
02/09/2024
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment [...]
Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000 Site Members
01/09/2024
WAKE FOREST, N.C. and ADELAIDE, Australia , Sept. 01, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning market-leading CRO for biotechs, announced today that 2,000 clinical sites across North America had [...]
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
01/09/2024
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE [...]
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
01/09/2024
Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care Medications in Patients [...]
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
01/09/2024
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarkers with Aficamten [...]
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
31/08/2024
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials testing multi- [...]
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
31/08/2024
SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Avricore Grants Options
31/08/2024
VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) today announces that the Company’s board of directors has approved the granting of stock [...]
Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024
30/08/2024
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30/08/2024
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences [...]
Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus
30/08/2024
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BOCA RATON, Fla., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: [...]
Receipt of Nasdaq Delisting Determination - Plans to Appeal
30/08/2024
August 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage [...]

Pages